

-continued

&lt;213&gt; ORGANISM: Artificial Sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Description of Artificial Sequence: Synthetic oligonucleotide

&lt;400&gt; SEQUENCE: 4

uugauguguu uagucgcua u

21


What is claimed:

1. A nanoparticle comprising:

- (a) a first polymer containing a polyol coupled to a second polymer containing a phenylboronic acid;
- (b) a ligand for a first cellular receptor; and
- (c) a therapeutic agent.

2. The nanoparticle of claim 1 wherein, in the first polymer, the polyol is a mucic acid polymer (MAP).


3. The nanoparticle of claim 2, wherein the mucic acid polymer contains repeating units comprising:



wherein:

n is 1.

4. The nanoparticle of claim 3, wherein the mucic acid polymer has the structural unit:

derived from the coupling of A and B;  
wherein A is


and

wherein:

sugar is mucic acid,  
spacer is  $-\text{CH}_2-\text{CH}_2-\text{NH}-$ ,  
L is a leaving group, and  
p is from 20-200.

5. The nanoparticle of claim 1 wherein, in the second polymer, the phenylboronic acid is a nitrophenylboronic acid.

6. The nanoparticle of claim 5, wherein the second polymer has the structure:




and isomers thereof wherein:

- (a) the PEG moiety is attached to the phenyl ring in an ortho or a para position relative to the boronic acid moiety, and/or
- (b) the nitro group is attached to the phenyl ring in an ortho or a para position relative to the boronic acid moiety; and


wherein s is from 20-300, and

functional group 2 comprises the ligand for a first cellular receptor.

7. The nanoparticle of claim 1, wherein the ligand for a first cellular receptor is a protein.



Bis



8. The nanoparticle of claim 7, wherein the protein is an antibody directed to the first cellular receptor.

9. The nanoparticle of claim 8, wherein the antibody is Herceptin®.

10. The nanoparticle of claim 1, wherein the therapeutic agent is a small molecule chemotherapeutic.

11. The nanoparticle of claim 10, wherein the small molecule chemotherapeutic is selected from the group consisting of camptothecin, a camptothecin-based drug, an epothilone and a taxane.